Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Escin→

Escin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
6805-41-0
Molecular formula
C110H172O48
Molecular weight
2262.5 g/mol
Drug class
Triterpene saponin mixture from horse chestnutvenotonic and capillary-protective agent
Mechanism of action
May reduce capillary permeability and oedema and improve venous tone through effects on endothelial and vascular smooth-muscle function. The pharmacological contribution of individual saponins and clinical mechanism are not fully established.
Indications / reported uses
  • Symptomatic treatment of chronic venous insufficiency, including leg swelling, heaviness and discomfort, with authorised horse-chestnut extract preparations standardised for escin; product and jurisdiction-specific

Sources: EMA herbal monograph — Aesculus hippocastanum seed · NCCIH — Horse chestnut · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Escin Environmental Risk Assessment (ERA) (the Escin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.